EFFECT OF TOBRAMYCIN INHALATION SOLUTION ON MORTALITY IN SUBGROUPS OF PATIENTS WITH CYSTIC FIBROSIS

被引：0
|
作者：
Latremouille-Viau, D. [1 ]
Sawicki, G. S. [2 ]
Zhang, J. [3 ]
von Wartburg, M. [1 ]
Signorovitch, J. [1 ]
Wu, E. Q. [1 ]
Shi, L. [4 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Childrens Hosp, Div Resp Dis, Boston, MA 02115 USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Tulane Univ, New Orleans, LA 70118 USA
来源：
PEDIATRIC PULMONOLOGY | 2011年
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：346 / 346
页数：1
相关论文
共 50 条
  • [31] MEDICATION ADHERENCE COMPARING TOBRAMYCIN INHALATION POWDER AND SOLUTION IN PATIENTS WITH CYSTIC FIBROSIS USING THE DUTCH PHARMO DATABASE NETWORK
    Overbeek, J.
    Kuiper, J.
    Evers, K.
    Putzeist, M.
    Mastoridis, P.
    Ong, S. H.
    Herk-Sukel, M.
    [J]. PEDIATRIC PULMONOLOGY, 2015, 50 : 365 - 365
  • [32] Inhalation of tobramycin in cystic fibrosis - Part 1: The choice of a nebulizer
    Le Brun, PPH
    de Boer, AH
    Gjaltema, D
    Hagedoorn, P
    Heijerman, HGM
    Frijlink, HW
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 189 (02) : 205 - 214
  • [33] COMPARISON OF COSTS & UTILIZATION OF AZTREONAM FOR INHALATION SOLUTION (AZLI) & TOBRAMYCIN INHALATION SOLUTION (TIS) IN CYSTIC FIBROSIS PATIENTS WITH P. AERUGINOSA INFECTION IN THE UNITED STATES
    Daines, C. L.
    Nakamura, C.
    Montgomery, B.
    Oermann, C. M.
    [J]. PEDIATRIC PULMONOLOGY, 2010, : 314 - 315
  • [34] AZTREONAM FOR INHALATION SOLUTION (AZLI) VS. TOBRAMYCIN INHALATION SOLUTION (TIS), A 6-MONTH COMPARATIVE TRIAL IN CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
    Oermann, C. M.
    Assael, B.
    Nakamura, C.
    Boas, S. R.
    Bresnik, M.
    Montgomery, A. B.
    Pressler, T.
    [J]. PEDIATRIC PULMONOLOGY, 2010, : 327 - 327
  • [35] Inhalation of tobramycin using simulated cystic fibrosis patient profiles
    Haynes, Alfred
    Geller, David
    Weers, Jeffry
    Ament, Brian
    Pavkov, Richard
    Malcolmson, Richard
    Debonnett, Laurie
    Mastoridis, Paul
    Yadao, Anthony
    Heuerding, Silvia
    [J]. PEDIATRIC PULMONOLOGY, 2016, 51 (11) : 1159 - 1167
  • [36] A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients
    Nikolaizik, Wilfried H.
    Vietzke, Delia
    Ratjen, Felix
    [J]. CANADIAN RESPIRATORY JOURNAL, 2008, 15 (05) : 259 - 262
  • [37] Tobramycin and colistin inhalation differentially modulate pulmonary host defense in cystic fibrosis patients
    Hartl, D.
    Kappler, M.
    Latzin, P.
    Schreiner, M.
    Wassilewa, M.
    Fischer, R.
    Mehlhorn, A.
    Marcos, V.
    Reinhardt, D.
    Roos, D.
    Griese, M.
    [J]. PEDIATRIC PULMONOLOGY, 2007, : 334 - 334
  • [38] One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis
    Konstan, Michael W.
    Flume, Patrick A.
    Galeva, Ivanka
    Wan, Robert
    Debonnett, Laurie M.
    Maykut, Robert J.
    Angyalosi, Gerhild
    [J]. PEDIATRIC PULMONOLOGY, 2016, 51 (04) : 372 - 378
  • [39] Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
    Konstan, Michael W.
    Flume, Patrick A.
    Kappler, Matthias
    Chiron, Raphael
    Higgins, Mark
    Brockhaus, Florian
    Zhang, Jie
    Angyalosi, Gerhild
    He, Ellie
    Geller, David E.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2011, 10 (01) : 54 - 61
  • [40] Rate of Hospitalizations Due to Respiratory Events With Tobramycin Inhalation Powder in Patients With Cystic Fibrosis
    Fiel, Stanley
    Nasr, Samya
    Wan, Robert
    Angyalosi, Gerhild
    Brockhaus, Florian
    Maykut, Robert
    Yadao, Anthony
    [J]. CHEST, 2013, 144 (04)
12345